FY2025 Earnings Estimate for Alector Issued By HC Wainwright

Alector, Inc. (NASDAQ:ALEC) – Analysts at HC Wainwright boosted their FY2025 earnings estimates for Alector in a report issued on Monday, November 10th. HC Wainwright analyst A. Fein now expects that the company will earn ($1.39) per share for the year, up from their prior forecast of ($1.64). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share. HC Wainwright also issued estimates for Alector’s Q4 2025 earnings at ($0.34) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at ($1.61) EPS, FY2028 earnings at ($1.39) EPS and FY2029 earnings at ($1.14) EPS.

Alector (NASDAQ:ALEC) last posted its earnings results on Thursday, November 6th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.08. The business had revenue of $3.26 million during the quarter, compared to the consensus estimate of $3.49 million. Alector had a negative net margin of 156.03% and a negative return on equity of 123.02%. Alector has set its FY 2025 guidance at EPS.

Several other research analysts have also recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Alector in a research report on Wednesday, October 8th. BTIG Research downgraded shares of Alector from a “buy” rating to a “neutral” rating in a report on Wednesday, October 22nd. William Blair cut shares of Alector from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 22nd. TD Cowen downgraded shares of Alector from a “buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Finally, Cantor Fitzgerald downgraded shares of Alector from an “overweight” rating to a “neutral” rating in a research report on Wednesday, October 22nd. One analyst has rated the stock with a Buy rating, seven have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $3.00.

Alector Stock Performance

Shares of ALEC opened at $1.36 on Wednesday. The firm has a market capitalization of $148.44 million, a P/E ratio of -1.27 and a beta of 0.93. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.76 and a quick ratio of 3.76. Alector has a one year low of $0.87 and a one year high of $6.05. The business has a fifty day moving average of $2.55 and a 200 day moving average of $1.93.

Hedge Funds Weigh In On Alector

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Alector by 0.8% during the third quarter. Vanguard Group Inc. now owns 6,034,659 shares of the company’s stock worth $17,863,000 after purchasing an additional 46,955 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Alector by 199.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 136,385 shares of the company’s stock worth $404,000 after purchasing an additional 90,894 shares during the period. Lexington Partners L.P. purchased a new stake in Alector during the 3rd quarter valued at approximately $30,000. Savant Capital LLC purchased a new stake in Alector during the 3rd quarter valued at approximately $35,000. Finally, Pinegrove Venture Partners LLC bought a new stake in shares of Alector during the third quarter valued at approximately $30,000. Institutional investors own 85.83% of the company’s stock.

Insider Transactions at Alector

In other Alector news, Director Paula Hammond sold 14,000 shares of the stock in a transaction on Tuesday, August 26th. The stock was sold at an average price of $2.36, for a total value of $33,040.00. Following the completion of the sale, the director owned 74,909 shares in the company, valued at approximately $176,785.24. This represents a 15.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 9.70% of the company’s stock.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.